A Non-interventional Study Investigating Semaglutide in Combination With Lifestyle-based Modifications for the Management of Obesity in Real-World Clinical Practice in Germany (WeGo Real Germany).
← catalyst calendarSponsored by Novo Nordisk A/S (industry) · NVO — their whole pipeline →.
Phase
—
Status
Terminated
Study type
Observational
Enrollment
100actual
Sites
1
Country
Germany
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
The study was cancelled prematurely due to lack of patients.
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-08-08 | actual | When the study began enrolling |
| Primary completion | 2025-12-18 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-12-18 | actual | The whole study's end, after follow-up |
| First posted | 2025-07-23 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-27 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Obesity
Intervention
- Drug: Semaglutide
Primary outcome
what the primary-completion date above is the date OFChange in relative body weight
measured From baseline to month 6 and month 9
Permalink · NVO's whole pipeline · Catalyst calendar · Every registered study · What changed